FDA Panel Reviews Diabetes Drug

By: Ashton King Email
By: Ashton King Email

An FDA panel meets Tuesday to consider pulling the diabetes drug Avandia from the market.

Dozens of studies have linked the former GlaxoSmithKline best-seller to an increased risk of heart attack.

Government scientists say studies conducted by the company are flawed and actually make the case against Avandia.

The panel will make its recommendation to the FDA after a two-day review of the drug's performance.

You must be logged in to post comments.

Password (case sensitive):
Remember Me:
WTVY-TV 285 N Foster Street Dothan, AL 36303 334-792-3195
Copyright © 2002-2016 - Designed by Gray Digital Media - Powered by Clickability 98300259 - wtvy.com/a?a=98300259
Gray Television, Inc.